U.S. and European Endocrinologists See a Continued Need for New Nonstatin Drugs with Cardiovascular Outcomes Benefits for Dyslipidemias

Decision Resources Group Logo.BURLINGTON, Mass., July 13, 2016 /PRNewswire/ — Decision Resources Team discovers that regardless of the several treatments accessible, there’s a continuing requirement for medicines that enhance LDLC. Excellent results from Ezetimibeis outcomes test (ENHANCE-IT) reinforced the LDLC recommend and speculation…

Leave a Reply

Your email address will not be published. Required fields are marked *